![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » Takeda’s Pevonedistat Gets Breakthrough Therapy Designation
Takeda’s Pevonedistat Gets Breakthrough Therapy Designation
July 31, 2020
The FDA granted a breakthrough therapy designation to Takeda Pharmaceuticals’ pevonedistat for patients with higher-risk myelodysplastic syndromes (HR-MDS), a rare form of bone marrow cancer.
The designation was granted based on a phase 2 clinical trial of pevonedistat plus azacitidine versus azacitidine alone in patients with rare leukemias, including HR-MDS.
Pevonedistat is currently in phase 3 studies as a first-line treatment for patients with HR-MDS and higher-risk chronic myelomonocytic leukemia.
Upcoming Events
-
21Oct